Network | Jotup

Xerox to deploy Verizon Network as a Service Solutions framework for IT modernization

Retrieved on:

Tuesday, February 27, 2024

NEW YORK, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Verizon Business today announced Xerox Holdings Corporation (NASDAQ: XRX) is adopting Verizon’s Network as a Service (NaaS) Solutions framework to accelerate the organization’s Reinvention and operating model evolution.

Key Points:

NEW YORK, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Verizon Business today announced Xerox Holdings Corporation (NASDAQ: XRX) is adopting Verizon’s Network as a Service (NaaS) Solutions framework to accelerate the organization’s Reinvention and operating model evolution.
“This collaboration with Xerox underscores our commitment to enabling our customers to thrive in the digital age,” said Massimo Peselli, CRO, Verizon Business.
“Verizon’s intelligent network framework is designed to empower enterprises to embrace the future of network services, providing unparalleled flexibility and scalability.
Additional services include; Verizon Operational and Financial Governance, Contact Center Management, Network and Security Consulting Services and Verizon Maintenance across the Network utilizing Verizon Care.

Broadcom and Vodafone Demonstrate Network Programmability to Optimize Network Performance for Short-Form Video Content

Retrieved on:

Tuesday, February 27, 2024

Architecture, Intelligence, Mobile, POC, Network architecture, RAN, Congestion, API, Lead, Mobile World Congress, Application, CSP, Network, Radio access network, Congress, VMware, VOD, RIC, Mobile phone

The joint effort showcases the benefits of applying network programmability and intelligence into the Radio Access Network (RAN), enhancing overall performance for customers.

Key Points:

The joint effort showcases the benefits of applying network programmability and intelligence into the Radio Access Network (RAN), enhancing overall performance for customers.
The emergence and rapid expansion of short-form video content is placing greater capacity demands on Communication Service Provider (CSP) networks globally.
To address these network challenges, Vodafone is implementing innovative solutions aimed at continuously enhancing the network performance for its customers.
The Network Programmability PoC will be showcased in both the VMware stand as well as Vodafone’s located in Hall 3 Stand 3E11.

Tech Industry Leader and Boardroom Powerhouse Maggie Wilderotter Joins Fortinet Board of Directors

Retrieved on:

Thursday, February 22, 2024

Frontier Communications, Certification, Fortune 500, TAA, DocuSign, Research, Growth, Xerox, Fortinet, Costco, Frontier, DreamWorks Animation, Network, Organization, Education outreach, Hewlett Packard Enterprise, Telecommunications, Microsoft, Management

SUNNYVALE, Calif., Feb. 22, 2024 (GLOBE NEWSWIRE) --

Key Points:

“We’re pleased to welcome Maggie Wilderotter to our esteemed board of directors.
With this appointment, Maggie transitions her talents from serving as a Fortinet Strategic Advisory Council (FSAC) member, where she gained valuable visibility and insights into Fortinet’s business and vision, to a board member.
Maggie is a seasoned business leader known for her distinguished career leading both Fortune 500 corporations and start-up enterprises in the technology and telecommunications sectors.
Maggie has also held board positions across various industries, contributing her expertise and leadership to diverse organizations.

PDAC 2024: The World’s Premier Mineral Exploration & Mining Convention

Retrieved on:

Thursday, February 22, 2024

Prospectors, Student, Mining, Metro Toronto Convention Centre, Coffee, Network, PDAC, Fairmont Royal York, Corporation

TORONTO, Feb. 22, 2024 (GLOBE NEWSWIRE) -- The Prospectors & Developers Association of Canada’s (PDAC) 2024 Convention – The World’s Premier Mineral Exploration & Mining Showcase – will commence March 3-6, 2024 in Toronto.

Key Points:

TORONTO, Feb. 22, 2024 (GLOBE NEWSWIRE) -- The Prospectors & Developers Association of Canada’s (PDAC) 2024 Convention – The World’s Premier Mineral Exploration & Mining Showcase – will commence March 3-6, 2024 in Toronto.
“After 92 years, PDAC’s annual Convention in Toronto is still the event-of-choice for the world’s mineral exploration industry’s leaders, companies, executives, government representatives, students, scientists, and anyone involved or interested in mineral exploration and development,” said Raymond Goldie, PDAC President.
Toronto is the mining investment capital of the world and Canada is home to more than half the world’s mining and exploration company headquarters.
If networking is your thing, you'll be delighted with our brand-new Coffee Connections and Happy Hours.

Draft guideline on allergen products development for immunotherapy and allergy diagnosis in moderate to low-sized study populations

Retrieved on:

Tuesday, March 12, 2024

Filtration, Vespula, Toxicity, Histamine, EAACI, Immunotherapy, Asthma, Report, Allergy, Skin, Pregnancy, PR, EEC, MITES, RNA, Criterion, History, CMR, Contraindication, HEP, Draft, Guideline, Patient, Ames test, Diagnosis, Dermatitis, Venom, Literature, Trial of the century, Reproduction, Silicon–germanium, SPT, Food allergy, Cosmetics, EECS, Absorption, Marketing, Safety, Data collection, Directive 2001/83/EC, GMP, ID50, Antibody, Documentation, European, Type IV hypersensitivity, Genotoxicity, Applicant (sketch), Aeroallergen, CHMP, PRIME, Immunoglobulin G, Type, Publication, Biology, Pollen, DNA, Environment, Immune system, Toolbox, NLN, AIT, Atopic dermatitis, Fatality, Chapter, Anaphylaxis, Process validation, ICH, Antigen, Rhinitis, Clinical trial, Erythema, Knowledge, Prescription, Human, Network, Medication, Scope, VIT, ICT, EMA, Collection, Macrophage, Outline, Metabolism, Registry, Inflammation, Immunoglobulin E, Nature, European Pharmacopoeia, Food, Risk, Prevalence, Mastocytosis, Observation, Cytokine, NPP, Patient safety, Disease, Finished, Medical device

16

Key Points:

16
Guideline on allergen products development for
immunotherapy and allergy diagnosis in moderate to lowsized study populations

17

Table of contents

18

Executive summary ..................................................................................... 3

19

1.
Specific effects ................................................................................................. 17
14
15

Guideline on allergen products development for immunotherapy and allergy diagnosis
in moderate to low-sized study populations
EMA/CHMP/72790/2024

Page 2/18

53

12.
Management for allergies may involve avoidance of the allergen, medications to relieve
66

symptoms, or allergen immunotherapy (AIT) to desensitize the immune system to the allergen.
71
Recommendations are made on the clinical development, potential study designs and safety

72

considerations for allergen products within the scope of the guideline.
Guideline on allergen products development for immunotherapy and allergy diagnosis
in moderate to low-sized study populations
EMA/CHMP/72790/2024
Page 3/18

88

While allergen specific immunotherapy is the only known disease modifying therapy for type I allergies,

89

there is no such treatment available for type IV allergies.
93
Several guidelines applicable for allergen products are available (see section 3) and provide advice on

94

quality and clinical development according to the current knowledge.
Guideline on allergen products development for immunotherapy and allergy diagnosis
in moderate to low-sized study populations
EMA/CHMP/72790/2024
Page 4/18

127

However, this guideline does not cover the indication of atopic dermatitis or asthma as these

128

conditions will require separate clinical trials (see Section 6).
129
In addition, the guideline does not cover medicinal allergen products manufactured using recombinant

130

DNA technology, synthetic peptides, DNA or RNA constructs and/or cell preparations as they differ

131

substantially to the allergen products as discussed above.
1
156

?

Guideline on the clinical development of products for specific immunotherapy for the treatment

157
158

of allergic diseases - CHMP/EWP/18504/2006
?

159
160
161

Guideline on Allergen Products: Production and Quality Issues EMEA/CHMP/BWP/304831/2007

?

Guideline on process validation for finished products - information and data to be provided in
regulatory submissions - EMA/CHMP/CVMP/QWP/BWP/70278/2012-Rev1, Corr.1

Guideline on allergen products development for immunotherapy and allergy diagnosis
in moderate to low-sized study populations
EMA/CHMP/72790/2024

Page 5/18

162

?

Recommendations on common regulatory approaches for allergen products - CMDh/399/2019

163

4.
In any
199

case, a reduced validation should include all relevant manufacturing process steps that are considered
Guideline on allergen products development for immunotherapy and allergy diagnosis
in moderate to low-sized study populations
EMA/CHMP/72790/2024

Page 6/18

200

product specific.
290
Diagnostic allergen products (Type I allergy)

291

A possible target indication is diagnosis of type I hypersensitivity (immediate-type allergy) by prick,

292

intracutaneous or provocation testing.
298
Guideline on allergen products development for immunotherapy and allergy diagnosis
in moderate to low-sized study populations
EMA/CHMP/72790/2024

Page 9/18

305
306

7.1.
Guideline on allergen products development for immunotherapy and allergy diagnosis
in moderate to low-sized study populations
EMA/CHMP/72790/2024
Page 11/18

377

8.
Clinical development of products for AIT: Study design,
efficacy and safety
378

In general, the clinical development should be performed according to current guidelines.
In such single trial, the suitability as a test allergen as well as the
376

Guideline on allergen products development for immunotherapy and allergy diagnosis
in moderate to low-sized study populations
EMA/CHMP/72790/2024

Page 12/18

415

dose finding for the therapeutic allergen could be investigated.
Guideline on allergen products development for immunotherapy and allergy diagnosis
in moderate to low-sized study populations
EMA/CHMP/72790/2024
Page 13/18

454
455

8.2.1.
493
Guideline on allergen products development for immunotherapy and allergy diagnosis
in moderate to low-sized study populations
EMA/CHMP/72790/2024

Page 15/18

527

In general, sensitivity and specificity of the product should be determined.
540
Guideline on allergen products development for immunotherapy and allergy diagnosis
in moderate to low-sized study populations
EMA/CHMP/72790/2024

Page 16/18

561

10.2.
Guideline on allergen products development for immunotherapy and allergy diagnosis
in moderate to low-sized study populations
EMA/CHMP/72790/2024
Page 17/18

595

4.
Allergol Immunopathol, 1989;
602

17(2):53-65

603

Guideline on allergen products development for immunotherapy and allergy diagnosis
in moderate to low-sized study populations
EMA/CHMP/72790/2024

Page 18/18

Saudia Cargo Goes Live with RTS Velocity and AcceleRate and Foresight Solutions

Retrieved on:

Thursday, March 7, 2024

Revenue Technology Services (RTS), provider of profit optimization tools for the travel and transportation industry, announced that Saudia Cargo, one of the world’s leading cargo airlines, went live with RTS Velocity, AcceleRate and Foresight solutions as part of a phased approach.

Key Points:

Revenue Technology Services (RTS), provider of profit optimization tools for the travel and transportation industry, announced that Saudia Cargo, one of the world’s leading cargo airlines, went live with RTS Velocity, AcceleRate and Foresight solutions as part of a phased approach.
These two solutions work seamlessly together to enhance efficiency for Saudia Cargo.
Mansour Alasmi added: “With RTS's cutting-edge solutions Velocity, AcceleRate and Foresight seamlessly integrated into our operations, we're empowered to make data-driven pricing decisions.
This accomplishment strengthens our global partnership, setting new standards and inspiring us to reach even greater heights.”
Mukundh Parthasarathy, Head of Cargo solutions at RTS, said: “Our vision of an end-to-end decision support solution suite for cargo has been realized with Saudia Cargo with Velocity, Foresight and AcceleRate.

Bluebird Network Welcomes Jason W. Adkins as Chief Executive Officer

Retrieved on:

Wednesday, March 6, 2024

Technology, Networks, Internet, Telecommunications, Marketing, Telcove, Multimedia, Level 3 Communications, Growth, Radford University, Sale, Cox Communications, MBA, Windstream Holdings, KDL, Network, Economics, Mobile phone

Bluebird Network , a communications infrastructure provider and operator of more than 11,000 miles of fiber and two data centers, is excited to announce the hiring of Jason W. Adkins as new Chief Executive Officer.

Key Points:

Bluebird Network , a communications infrastructure provider and operator of more than 11,000 miles of fiber and two data centers, is excited to announce the hiring of Jason W. Adkins as new Chief Executive Officer.
View the full release here: https://www.businesswire.com/news/home/20240306795597/en/
Jason W. Adkins joins Bluebird Network as new Chief Executive Officer (Photo: Business Wire)
Adkins, a twenty nine-year fiber industry veteran, previously served as CEO of Unite Private Networks until their recent sale to Cox Communications.
“I am incredibly excited to be given the opportunity to lead the talented and dedicated employees of Bluebird Network,” says Adkins.
“Jason is just the right person to continue the growth at Bluebird Network.”
To learn more about Bluebird Network and its plans for the future, visit their website at https://bluebirdnetwork.com/

Butterfly Network to Participate at the Oppenheimer 34th Annual Healthcare MedTech & Services Conference

Retrieved on:

Wednesday, March 6, 2024

Butterfly Network, Inc. (NYSE: BFLY) (“Butterfly”) a digital health company transforming care with handheld, whole-body ultrasound and intuitive software, today announced that Joseph DeVivo, President, Chief Executive Officer and Chairman, and Heather Getz, Executive Vice President, Chief Financial and Operations Officer, will participate in a fireside chat and host one-on-one investor meetings at the Oppenheimer 34th Annual Healthcare MedTech & Services Conference on March 13, 2024, at 8:40 am ET.

Key Points:

Butterfly Network, Inc. (NYSE: BFLY) (“Butterfly”) a digital health company transforming care with handheld, whole-body ultrasound and intuitive software, today announced that Joseph DeVivo, President, Chief Executive Officer and Chairman, and Heather Getz, Executive Vice President, Chief Financial and Operations Officer, will participate in a fireside chat and host one-on-one investor meetings at the Oppenheimer 34th Annual Healthcare MedTech & Services Conference on March 13, 2024, at 8:40 am ET.
The conference will be held virtually.
A webcast of the fireside chat will be available in the Events & Presentations section of the Butterfly investor website, and available for replay following the event until June 11, 2024.
To schedule a one-on-one meeting with Mr. DeVivo and Ms. Getz, please reach out to your Oppenheimer representative.

Arista Introduces Universal Network Observability

Retrieved on:

Tuesday, March 5, 2024

Arista’s CloudVision® Universal Network Observability™ (CV UNO™) system, available as a premium feature license on Arista CloudVision, enables the automation of network, systems, and application/workload visibility, coupled with AI-driven proactive analysis and prescriptive recommendations, which significantly reduces human error, accelerates issue resolution for unforeseen events, and provides precise root cause analysis of network events and their impact on application delivery.

Key Points:

Arista’s CloudVision® Universal Network Observability™ (CV UNO™) system, available as a premium feature license on Arista CloudVision, enables the automation of network, systems, and application/workload visibility, coupled with AI-driven proactive analysis and prescriptive recommendations, which significantly reduces human error, accelerates issue resolution for unforeseen events, and provides precise root cause analysis of network events and their impact on application delivery.
“Bringing together multiple network domains with full application visibility and troubleshooting will streamline network operations and improve uptime and reliability.
This holistic data, coupled with CloudVision’s deep view of the networking state within Arista Network Data Lake (NetDL™) , CV UNO, presents a composite picture of the entire network and application environment.
“Arista’s Universal Network Observability, built upon Arista EOS® and CloudVision platforms, fulfills this critical client need.”
CV UNO consists of the following components:
CV UNO Sensor collects, normalizes, and curates flow/SNMP data from various sources like VMware vCenter, DANZ Monitoring Fabric, and third-party network devices and forwards them to NetDL.

Bigleaf Networks Unveils Proprietary Wireless Solution, Bigleaf Wireless Connect

Retrieved on:

Tuesday, March 5, 2024

Technology, Mobile, Wireless, Networks, Internet, Network, Organization, Verizon Communications, AT&T, Mobile phone

Bigleaf Networks , a leading provider of network optimization solutions, today announced the launch of its latest offering, Bigleaf Wireless Connect.

Key Points:

Bigleaf Networks , a leading provider of network optimization solutions, today announced the launch of its latest offering, Bigleaf Wireless Connect.
Convenient billing: Bigleaf Wireless Connect co-terms with the Bigleaf SD-WAN service at the designated site.
24x7 one-stop support: A top-rated team of network engineers supports both the Bigleaf SD-WAN service and the Bigleaf Wireless Connect solution.
Integrating Bigleaf Wireless Connect with a Bigleaf service and a primary connection streamlines the process of securing enhanced network reliability and uninterrupted access.